Latest news with #AurobindoPharmaLimited
&w=3840&q=100)
Business Standard
26-05-2025
- Business
- Business Standard
Aurobindo Pharma Q4 PAT falls marginally to ₹903 cr, revenue up 10%
Aurobindo Pharma Limited reported a marginal decline of 0.5 per cent in its net profit to ₹903 crore in the fourth quarter of financial year 2024–25 (Q4FY25), compared to ₹907 crore in the same period last year. The company's revenue from operations rose 10.6 per cent year-on-year (YoY) to ₹8,382 crore during the quarter, with growth seen across key business segments. Revenue from US formulations grew by 13.5 per cent YoY to ₹4,072 crore ($470 million), while Europe formulations posted stronger growth of 17.2 per cent YoY to ₹2,147 crore (€236 million). 'Our European operations continue to perform exceptionally well, moving steadily towards the $1 billion revenue milestone. Backed by our ongoing capacity enhancements, we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders,' said K Nithyananda Reddy, Vice-Chairman and Managing Director, Aurobindo Pharma. Revenue from Growth Markets declined 7.8 per cent YoY to ₹786 crore ($91 million), primarily due to moderated performance in select regions. The antiretroviral (ARV) segment recorded robust growth, with revenue rising 29.4 per cent YoY to ₹308 crore ($36 million), contributing 3.7 per cent to consolidated revenue. Active Pharmaceutical Ingredient (API) revenue increased by 5.0 per cent YoY to ₹1,069 crore ($124 million), accounting for 12.8 per cent of consolidated revenue. Operational and financial metrics EBITDA before R&D stood at ₹2,202 crore, with a margin of 26.3 per cent EBITDA before forex and other income was ₹1,792 crore, with a 21.4 per cent margin R&D expenditure, including depreciation, was ₹423 crore, amounting to 5.0 per cent of total revenue During the quarter, the company received final approval for five ANDAs from the US Food and Drug Administration (USFDA), including two previously tentatively approved. Earnings per share (EPS) for the quarter stood at ₹15.56, both basic and diluted. Domestic formulation sales stood at ₹56 crore during the quarter. The company's API revenue in dollar terms rose 0.7 per cent YoY to $124 million, while ARV revenue rose 24.1 per cent YoY to $36 million.
Business Upturn
28-04-2025
- Business
- Business Upturn
Aurobindo Pharma reports fire incident at Andhra Pradesh facility, operations temporarily paused
By Markets Desk Published on April 28, 2025, 19:15 IST Aurobindo Pharma Limited on Sunday informed exchanges about a fire incident at one of its manufacturing facilities operated by its wholly owned stepdown subsidiary, Lyfius Pharma Private Limited, located in the Kakinada SEZ, Andhra Pradesh. The incident took place late evening on April 27, 2025, around 10:00 PM IST. According to the company's regulatory filing, the fire broke out in the vicinity of the coal crusher area at its Penicillin-G manufacturing unit. While the fire led to damage of certain ancillary equipment, there was no impact on the core manufacturing infrastructure, and importantly, no injuries were reported among the staff. Aurobindo Pharma has clarified that the incident is not expected to have any material impact on the operations or financials of the group. The company emphasized that the facility is fully insured, and a thorough assessment of the damage is currently underway. As a precautionary measure and to facilitate necessary repairs and replacements, operations at the affected plant will be temporarily paused for approximately 20 to 25 days. The company added that it remains committed to resuming full operations at the earliest while adhering to the highest safety and quality standards. Aurobindo reassured stakeholders that all due protocols are being followed and that operations at other facilities continue as normal. Markets Desk at
Business Upturn
26-04-2025
- Business
- Business Upturn
Aurobindo Pharma subsidiary receives positive opinion for biosimilar Dazublys from EMA
By Aman Shukla Published on April 26, 2025, 09:57 IST CuraTeQ Biologics s.r.o., a subsidiary of Aurobindo Pharma Limited, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Dazublys® (150 mg powder for concentrate for solution for infusion). Dazublys® is a biosimilar to trastuzumab, developed for the treatment of HER2-positive metastatic and early breast cancers. Trastuzumab, the active ingredient in Dazublys®, targets and inhibits the HER2 protein, which is over-expressed in certain cancers, particularly breast and gastric cancer. By binding to the extracellular domain of HER2, trastuzumab disrupts its signaling, leading to cell cycle arrest, reduced tumor growth, and activation of the immune system to attack cancer cells. The positive CHMP opinion is an important step for Dazublys® towards securing marketing authorization in the European Union. This approval would provide healthcare professionals with an effective, cost-effective alternative for treating HER2-positive breast cancer, potentially improving access to vital cancer therapies. CuraTeQ Biologics is committed to enhancing patient outcomes with biosimilar medicines, offering an affordable treatment option for cancer patients. The company remains focused on expanding its portfolio of biosimilars to address critical healthcare needs. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
